血必净注射液联合哌拉西林钠他唑巴坦钠治疗重症肺炎的临床研究
|
摘要
目的探讨血必净注射液联合哌拉西林钠他唑巴坦钠治疗重症肺炎的临床疗效。方法将100例重症肺炎患者随机分为对照组和观察组,每组50例。对照组采用哌拉西林钠他唑巴坦钠治疗,观察组在对照组治疗基础上联合应用血必净注射液治疗。2组疗程均为10天。比较2组临床疗效、基础血清生化指标及特异性血清可溶性髓样细胞触发受体-1(soluble triggering receptor expressed on myeloid cells-1,sTREM-1)和IL-10水平。结果治疗后,观察组临床总有效率明显高于对照组(P<0.05);与对照组比较,观察组炎症指标(WBC、CRP)明显降低,肝功能指标(ALT、AST)显著降低,肾功能指标(Cr、BUN)明显下降,PaO_2显著升高,差异均有统计学意义(P<0.05);治疗后,2组血清sTREM-1与IL-10水平均显著下降(P<0.05),且观察组明显低于对照组(P<0.05);与对照组比较,观察组平均住院时间明显缩短(P<0.05);2组在治疗过程中均未出现明显不良反应。结论应用血必净注射液联合哌拉西林钠他唑巴坦钠治疗重症肺炎临床疗效显著,安全可靠,值得进一步推广与应用。
Objective To investigate the clinical efficacy of Xuebijing injection combined with piperacillin sodium and tazobactam sodium in the treatment of severe pneumonia.Methods One hundred patients with severe pneumonia were randomly divided into control group and observation group,with 50 cases in each group.The control group were treated with piperacillin sodium and tazobactam sodium,and the observation group was combined with Xuebijing injection based on the control group.The course of treatment in both groups was 10 days.The clinical treatment efficiency,the changes of basic serum biochemical indicators and specific serum soluble triggering receptor expressed on myeloid cells-1 and IL-10 before and after treatment were compared to evaluate the clinical effect of Xuebijing injection combined with piperacillin sodium and tazobactam sodium.Results After treatment,the total effective rate in the observation group was significantly higher than that in the control group(P<0.05).Compared with the control group,the inflammatory indexes(WBC,CRP),liver function indexes(ALT,AST),renal function indexes(Cr,BUN)in the observation group were significantly lower than those in the control group(P<0.05),and PaO_2 was significantly higher than that in the control group(P<0.05).The levels of serum sTREM-1 and IL-10 in the two groups were significantly decreased after treatment(P<0.05).And the serum sTREM-1 and IL-10 in the observation group were significantly lower than those in the control group(P<0.05).Compared with the control group,the average hospitalization time in the observation group was significantly shorter than that in the control group(P<0.05).There were no adverse reactions during the treatment in both groups.Conclusion The application of Xuebijing injection combined with piperacillin sodium and tazobactam sodium in patients with severe pneumonia is clinically effective,safe and reliable,which is worthy of further promotion and application.
Objective To investigate the clinical efficacy of Xuebijing injection combined with piperacillin sodium and tazobactam sodium in the treatment of severe pneumonia.Methods One hundred patients with severe pneumonia were randomly divided into control group and observation group,with 50 cases in each group.The control group were treated with piperacillin sodium and tazobactam sodium,and the observation group was combined with Xuebijing injection based on the control group.The course of treatment in both groups was 10 days.The clinical treatment efficiency,the changes of basic serum biochemical indicators and specific serum soluble triggering receptor expressed on myeloid cells-1 and IL-10 before and after treatment were compared to evaluate the clinical effect of Xuebijing injection combined with piperacillin sodium and tazobactam sodium.Results After treatment,the total effective rate in the observation group was significantly higher than that in the control group(P<0.05).Compared with the control group,the inflammatory indexes(WBC,CRP),liver function indexes(ALT,AST),renal function indexes(Cr,BUN)in the observation group were significantly lower than those in the control group(P<0.05),and PaO_2 was significantly higher than that in the control group(P<0.05).The levels of serum sTREM-1 and IL-10 in the two groups were significantly decreased after treatment(P<0.05).And the serum sTREM-1 and IL-10 in the observation group were significantly lower than those in the control group(P<0.05).Compared with the control group,the average hospitalization time in the observation group was significantly shorter than that in the control group(P<0.05).There were no adverse reactions during the treatment in both groups.Conclusion The application of Xuebijing injection combined with piperacillin sodium and tazobactam sodium in patients with severe pneumonia is clinically effective,safe and reliable,which is worthy of further promotion and application.
引文
[1] 刘雅芬,高燕.成人社区获得性肺炎病原流行病学及诊断研究进展[J].中华医学杂志,2013,93(4):317-319.
[2] 张虹.重症肺炎中西医结合防治概况[J].实用心脑肺血管病杂志,2010,18(12):1917-1920.
[3] Mandell LA,Wunderink RG,Anzueto A,et al.Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults[J].Clin Infect Dis,2007,44(Suppl 2):S27-S72.
[4] 国家中医药管理局.中医病证诊断疗效标准[M].南京:南京大学出版社,1994.
[5] 郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002.
[6] 王晨,陆刚,吴春荣,等.sTREM-1等几种生物标志物在兔白色念珠菌肺炎中的表达[J].中国免疫学杂志,2016,32(10):1512-1518.
[7] 曾小莉,张韶岩,郭晶,等.可溶性髓样细胞触发受体1在脓毒症中的表达和临床意义[J].中国呼吸与危重监护杂志,2011,10(6):538-542.
[8] 顾猛,刘春霞,张虹,等.重症肺炎患者血清和支气管肺泡灌洗液中IL-6和IL-10检测及其临床意义[J].中华全科医学,2008,6(2):133-134.
[2] 张虹.重症肺炎中西医结合防治概况[J].实用心脑肺血管病杂志,2010,18(12):1917-1920.
[3] Mandell LA,Wunderink RG,Anzueto A,et al.Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults[J].Clin Infect Dis,2007,44(Suppl 2):S27-S72.
[4] 国家中医药管理局.中医病证诊断疗效标准[M].南京:南京大学出版社,1994.
[5] 郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002.
[6] 王晨,陆刚,吴春荣,等.sTREM-1等几种生物标志物在兔白色念珠菌肺炎中的表达[J].中国免疫学杂志,2016,32(10):1512-1518.
[7] 曾小莉,张韶岩,郭晶,等.可溶性髓样细胞触发受体1在脓毒症中的表达和临床意义[J].中国呼吸与危重监护杂志,2011,10(6):538-542.
[8] 顾猛,刘春霞,张虹,等.重症肺炎患者血清和支气管肺泡灌洗液中IL-6和IL-10检测及其临床意义[J].中华全科医学,2008,6(2):133-134.